Review article: Bacteria and pathogenesis of disease in the upper gastrointestinal tract - Beyond the era of Helicobacter pylori

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 8, 2014, Pages 767-779

  Walker, M M ^a   Talley, N J ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL OVERGROWTH; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BARRETT ESOPHAGUS; CELIAC DISEASE; COLONY FORMING UNIT; DUODENUM; ERADICATION THERAPY; ESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HUMAN; INFECTION RISK; INTESTINE FLORA; IRRITABLE COLON; LOWER ESOPHAGUS SPHINCTER; MICROBIOME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; RISK BENEFIT ANALYSIS; STOMACH LYMPHOMA; UPPER GASTROINTESTINAL TRACT;

EID: 84896400379     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12666     Document Type: Review

References (116)

1. Turnbaugh PJ, Ley RE, Hamady M, et al,. The human microbiome project. Nature 2007; 449: 804-10.
2. Qin J, Li R, Raes J, Arumugam M, et al,. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
3. Cho I, Blaser MJ,. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13: 260-70.
4. Spor A, Koren O, Ley R,. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011; 9: 279-90.
5. Abreu MT,. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 2010; 10: 131-44.
6. Tilg H,. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroenterol 2010; 44 (Suppl. 1): S16-8.
7. Yang I, Nell S, Suerbaum S,. Survival in hostile territory: the microbiota of the stomach. FEMS Microbiol Rev 2013; 37: 736-61.
8. Kanno T, Matsuki T, Oka M, et al,. Gastric acid reduction leads to an alteration in lower intestinal microflora. Biochem Biophys Res Commun 2009; 381: 666-70.
9. Warren JR, Marshall B,. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 321: 1273-5.
10. Marshall BJ, Warren JR,. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-5.
11. Polk DB, Peek RM Jr,. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10: 403-14.
12. Norder Grusell E, Dahlén G, Ruth M, et al,. Bacterial flora of the human oral cavity, and the upper and lower esophagus. Dis Esophagus 2013; 26: 84-90.
13. Pei Z, Yang L, Peek RM Jr, et al,. Bacterial biota in reflux esophagitis and Barrett's esophagus. World J Gastroenterol 2005; 11: 7277-83.
14. Wang ZK, Yang YS,. Upper gastrointestinal microbiota and digestive diseases. World J Gastroenterol 2013; 19: 1541-50.
15. Di Cagno R, De Angelis M, De Pasquale I, et al,. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol 2011; 11: 219.
16. McGuckin MA, Lindén SK, Sutton P, Florin TH,. Mucin dynamics and enteric pathogens. Nat Rev Microbiol 2011; 9: 265-78.
17. Hofmann AF, Eckmann L,. How bile acids confer gut mucosal protection against bacteria. Proc Natl Acad Sci USA 2006; 103: 4333-4.
18. Faith JJ, Guruge JL, Charbonneau M, et al,. The long-term stability of the human gut microbiota. Science 2013; 341: 1237439.
19. Salama NR, Hartung ML, Müller A,. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol 2013; 11: 385-99.
20. Goh KL, Chan WK, Shiota S, et al,. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011; 16 (Suppl. 1): 1-9.
21. Queiroz DM, Harris PR, Sanderson IR, et al,. Iron status and Helicobacter pylori infection in symptomatic children: an international multi-centered study. PLoS ONE 2013; 8: e68833.
22. Pandeya N, Whiteman DC,. Prevalence and determinants of Helicobacter pylori sero-positivity in the Australian adult community. Australian Cancer Study. J Gastroenterol Hepatol 2011; 26: 1283-9.
23. Li Z, Zou D, Ma X, Chen J, et al,. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010; 105: 2570-7.
24. Aje AO, Otegbayo JA, Odaibo GN, et al,. Comparative study of stool antigen test and serology for Helicobacter pylori among Nigerian dyspeptic patients-a pilot study. Niger J Clin Pract 2010; 13: 120-4.
25. Ortega JP, Espino A, Calvo BA, et al,. Helicobacter pylori infection in symptomatic patients with benign gastroduodenal diseases: analysis of 5.664 cases. Rev Med Chil 2010; 138: 529-35.
26. Dattoli VC, Veiga RV, da Cunha SS, et al,. Seroprevalence and potential risk factors for Helicobacter pylori infection in Brazilian children. Helicobacter 2010; 15: 273-8.
27. Epplein M, Signorello LB, Zheng W, et al,. Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev 2011; 20: 826-34.
28. Sethi A, Chaudhuri M, Kelly L, Hopman W,. Prevalence of Helicobacter pylori in a First Nations population in northwestern Ontario. Can Fam Physician 2013; 59: e182-7.
29. Batts KP, Ketover S, Kakar S, et al,. Appropriate use of special stains for identifying Helicobacter pylori: recommendations from the Rodger C. Haggitt Gastrointestinal Pathology Society. Am J Surg Pathol 2013; 37: e12-22.
30. Bansil R, Celli JP, Hardcastle JM, Turner BS,. The influence of mucus microstructure and rheology in Helicobacter pylori infection. Front Immunol 2013; 4: 310.
31. Montecucco C, Rappuoli R,. Living dangerously: how Helicobacter pylori survives in the human stomach. Nat Rev Mol Cell Biol 2001; 2: 457-66.
32. Valkonen KH, Wadström T, Moran AP,. Identification of the N-acetylneuraminyllactose-specific laminin-binding protein of Helicobacter pylori. Infect Immun 1997; 65: 916-23.
33. Ferlay J, Shin HR, Bray F, Forman D, et al,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
34. Danaei G,. Global burden of infection-related cancer revisited. Lancet Oncol 2012; 13: 564-5.
35. Available at: http://globocan.iarc.fr/Default.aspx. Accessed September 2, 2013.
36. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347-53.
37. de Martel C, Ferlay J, Franceschi S, et al,. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-15.
38. Bhandari A, Crowe SE,. Helicobacter pylori in gastric malignancies. Curr Gastroenterol Rep 2012; 14: 489-96.
39. González CA, Lõpez-Carrillo L,. Helicobacter pylori, nutrition and smoking interactions: their impact in gastric carcinogenesis. Scand J Gastroenterol 2010; 45: 6-14.
40. Ikeda F, Doi Y, Yonemoto K, Ninomiya T, et al,. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 2009; 136: 1234-41.
41. de Martel C, Forman D, Plummer M,. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am 2013; 42: 219-40.
42. D'Elia L, Rossi G, Ippolito R, Cappuccio FP, et al,. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr 2012; 31: 489-98.
43. Zhu H, Yang X, Zhang C, et al,. Red and processed meat intake is associated with higher gastric cancer risk: a meta-analysis of epidemiological observational studies. PLoS ONE 2013; 8: e70955.
44. Ohnishi N, Yuasa H, Tanaka S, et al,. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA 2008; 105: 1003-8.
45. Chen Y, Segers S, Blaser MJ,. Association between Helicobacter pylori and mortality in the NHANES III study. Gut 2013; 62: 1262-9.
46. Malfertheiner P, Megraud F, O'Morain CA, et al,. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
47. Talley NJ, Fock KM, Moayyedi P,. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008; 103: 510-4.
48. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al,., EGILS Group. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747-58.
49. Zullo A, Hassan C, Cristofari F, Andriani A, et al,. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-10.
50. Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, et al,. T(11; 18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-94.
51. Wündisch T, Thiede C, Morgner A, Dempfle A, et al,. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 1: 8018-24.
52. Zullo A, Hassan C, Ridola L, De Francesco V, et al,. Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review. J Clin Gastroenterol 2013; 47: 824-7.
53. Gisbert JP, Calvet X,. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30: 791-815.
54. Mesnard B, De Vroey B, Maunoury V, et al,. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. Dig Liver Dis 2012; 44: 799-800.
55. Suarez F, Lortholary O, Hermine O, et al,. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006; 107: 3034-44.
56. Lecuit M, Abachin E, Martin A, et al,. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350: 239-48.
57. Dutta U, Udawat H, Noor MT, et al,. Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori. J Gastrointest Cancer 2010; 41: 212-5.
58. Fock KM, Graham DY, Malfertheiner P,. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol 2013; 10: 495-500.
59. Gatta L, Vakil N, Vaira D, et al,. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
60. Megraud F, Coenen S, Versporten A, et al,. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
61. Rolig AS, Cech C, Ahler E, et al,. The degree of Helicobacter pylori-triggered inflammation is manipulated by preinfection host microbiota. Infect Immun 2013; 81: 1382-9.
62. Ritchie ML, Romanuk TN,. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 2012; 7: e34938.
63. Lionetti E, Miniello VL, Castellaneta SP, et al,. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther 2006; 24: 1461-8.
64. Mehling H, Busjahn A,. Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients 2013; 5: 3062-73.
65. Wang Q, Yu C, Sun Y,. The association between asthma and Helicobacter pylori: a meta-analysis. Helicobacter 2013; 18: 41-53.
66. Chen Y, Blaser MJ,. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis 2008; 198: 553-60.
67. Amedei A, Cappon A, Codolo G, et al,. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006; 116: 1092-101.
68. Codolo G, Mazzi P, Amedei A, et al,. The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cell Microbiol 2008; 10: 2355-63.
69. Amedei A, Codolo G, Del Prete G, et al,. The effect of Helicobacter pylori on asthma and allergy. J Asthma Allergy 2010; 3: 139-47.
70. Blaser MJ, Falkow S,. What are the consequences of the disappearing human microbiota Nat Rev Microbiol 2009; 7: 887-94.
71. Baele M, Pasmans F, Flahou B, et al,. Non-Helicobacter pylori helicobacters detected in the stomach of humans comprise several naturally occurring Helicobacter species in animals. FEMS Immunol Med Microbiol 2009; 55: 306-13.
72. Chisholm SA, Owen RJ,. Development and application of a novel screening PCR assay for direct detection of 'Helicobacter heilmannii'-like organisms in human gastric biopsies in Southeast England. Diagn Microbiol Infect Dis 2003; 46: 1-7.
73. Haesebrouck F, Pasmans F, Flahou B, et al,. Gastric helicobacters in domestic animals and nonhuman primates and their significance for human health. Clin Microbiol Rev 2009; 22: 202-23.
74. Smet A, Flahou B, Mukhopadhya I, et al,. The other Helicobacters. Helicobacter 2011; 16 (Suppl. 1): 70-5.
75. Haesebrouck F, Pasmans F, Flahou B, et al,. Non-Helicobacter pylori Helicobacter species in the human gastric mucosa: a proposal to introduce the terms H. heilmannii sensu lato and sensu stricto. Helicobacter 2011; 16: 339-40.
76. Yakoob J, Abbas Z, Khan R, et al,. Prevalence of non Helicobacter pylori species in patients presenting with dyspepsia. BMC Gastroenterol 2012; 12: 3.
77. Bik EM,. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA 2006; 103: 732-7.
78. Li XX, Wong GL, To KF, Wong VW, et al,. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non- steroidal anti-inflammatory drug use. PLoS ONE 2009; 4: e7985.
79. Dicksved J, Lindberg M, Rosenquist M, et al,. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol 2009; 58: 509-16.
80. Lofgren JL, Whary MT, Ge Z, et al,. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 2011; 140: 210-20.
81. Lertpiriyapong K, Whary MT, Muthupalani S, et al,. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis. Gut 2014; 63: 54-63.
82. Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, et al,. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J 2011; 5: 574-9.
83. Moayyedi P, Talley NJ,. Gastro-oesophageal reflux disease. Lancet 2006; 367: 2086-100.
84. Brown TJ, Hooper L, Elliott RA, et al,. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006; 10: iii-iv, xi-xiii, 1-183.
85. Sharma BK, Santana IA, Wood EC, et al,. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J (Clin Res Ed) 1984; 289: 717-9.
86. Dial MS,. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009; 104 (2 Suppl.): S10-6.
87. Kwok CS, Arthur AK, Anibueze CI, et al,. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1011-9.
88. Lundell L, Havu N, Miettinen P, Myrvold HE, et al,. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006; 23: 639-47.
89. Marcus EA, Vagin O, Tokhtaeva E, et al,. Helicobacter pylori impedes acid-induced tightening of gastric epithelial junctions. Am J Physiol Gastrointest Liver Physiol 2013; 305: G731-9.
90. Gales D, Clark C, Manne U, et al,. The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol 2013; 2013: m859154.
91. Correa P,. Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res 1992; 52: 6735-40.
92. Forman D, Burley VJ,. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006; 20: 633-49.
93. Pei Z, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ,. Bacterial biota in the human distal esophagus. Proc Natl Acad Sci U S A 2004; 101: 4250-5.
94. Seenan JP, Wirz AA, Robertson EV, et al,. Effect of nitrite delivered in saliva on postprandial gastro-esophageal function. Scand J Gastroenterol 2012; 47: 387-96.
95. Yang L, Lu X, Nossa CW, et al,. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 2009; 137: 588-97.
96. Suerbaum S,. Microbiome analysis in the esophagus. Gastroenterology 2009; 137: 419-21.
97. Fan YP, Chakder S, Gao F, et al,. Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction. Am J Physiol Gastrointest Liver Physiol 2001; 280: 80.
98. Calatayud S, García-Zaragozá E, Hernández C, et al,. Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1360-7.
99. Amir I, Konikoff FM, Oppenheim M, et al,. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ Microbiol 2013; doi: 10.1111/1462-2920.12285 [Epub ahead of print].
100. Fleissner CK, Huebel N, Abd El-Bary MM, et al,. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr 2010; 104: 919-29.
101. Blot WJ, Devesa SS, Kneller RW, et al,. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-9.
102. Buas MF, Vaughan TL,. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol 2013; 23: 3-9.
103. Chow WH, Blaser MJ, Blot WJ, et al,. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 588-90.
104. Kamangar F, Dawsey SM, Blaser MJ, et al,. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006; 98: 1445-52.
105. Whiteman DC, Parmar P, Fahey P, et al,.; Australian Cancer Study Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 2010; 139: 73-83.
106. Thrift AP, Pandeya N, Smith KJ, et al,. Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int J Cancer 2012; 130: 2407-16.
107. Spiegel BM,. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol 2011; 9: 461-9.
108. Leonard J, Marshall JK, Moayyedi P,. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-56.
109. Yu D, Cheeseman F, Vanner S,. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011; 60: 334-40.
110. Kerckhoffs AP, Samsom M, van der Rest ME, et al,. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887-92.
111. Kerckhoffs AP, Ben-Amor K, Samsom M, et al,. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. J Med Microbiol 2011; 60: 236-45.
112. Carey CM, Kostrzynska M, Ojha S, et al,. The effect of probiotics and organic acids on Shiga-toxin 2 gene expression in enterohemorrhagic Escherichia coli O157: H7. J Microbiol Methods 2008; 73: 125-32.
113. Brenner DM, Moeller MJ, Chey WD, et al,. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-49.
114. Iebba V, Santangelo F, Totino V, et al,. Higher prevalence and abundance of Bdellovibrio bacteriovorus in the human gut of healthy subjects. PLoS ONE 2013; 8: e61608.
115. Atterbury RJ, Hobley L, Till R, et al,. Effects of orally administered Bdellovibrio bacteriovorus on the well-being and Salmonella colonization of young chicks. Appl Environ Microbiol 2011; 77: 5794-803.
116. Wacklin P, Kaukinen K, Tuovinen E, et al,. The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease. Inflamm Bowel Dis 2013; 19: 934-41.